Other approaches are currently under clinical investigation, including PD-1 deletion and cytokine signaling modulation (dominant-negative TGF-β receptor, etc.)to improve T-cell function, as well as several armored T-cell products aimed at altering the hostile tumor microenvironment (as described above), but very limited published clinical data are available. This evidence concerns the gene PDCD1 and neoplasm.